Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02400242 · ClinicalTrials.gov registry record · Phase 1
Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma
A Phase 1 study, sponsored by Celgene.
- Terminated
- Registry status
- Phase 1
- Development phase
- 85
- Enrollment target
NCT02400242 is a Phase 1 study that was terminated before completion, run by Celgene. The registered enrollment target is 85 participants.
The verdict
NCT02400242, a Phase 1 study, was terminated before completion, sponsored by Celgene.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 85 participants
- Enrollment target
Study Summary
This is a phase 1a/1b, multicenter, single-arm, open-label, dose escalation study to determine the maximum tolerated dose (MTD) and evaluate the safety and preliminary antitumor activity of ACY-241 for oral administration as monotherapy and in combination therapy with orally administered pomalidomide and low-dose dexamethasone in eligible patients with relapsed or relapsed-and-refractory multiple myeloma (MM).
Interventions
- DRUG Dexamethasone
- DRUG Pomalidomide
- DRUG ACY-241
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2015-05-07 |
| Est. Completion | 2024-06-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02400242
The ClinicalTrials.gov registry entry for NCT02400242 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Dexamethasone is the first listed.
NCT02400242 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02400242 about?
NCT02400242 is a clinical study titled "Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma". This is a phase 1a/1b, multicenter, single-arm, open-label, dose escalation study to determine the maximum tolerated dose (MTD) and evaluate the safety and preliminary antitumor activity of ACY-241 for oral administration as monotherapy and in combination therapy with orally administered pomalidomid...
What is the current status of trial NCT02400242?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 85 participants. The study started on 2015-05-07. Estimated completion is 2024-06-03.
What interventions are being tested in trial NCT02400242?
The interventions under investigation include: Dexamethasone (DRUG), Pomalidomide (DRUG), ACY-241 (DRUG).
Who is sponsoring clinical trial NCT02400242?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.